XERXES: Examining the role of early neoadjuvant and synchronous Erbitux in pre-operative chemo-radiotherapy using Xeloda followed by excisional surgery. A phase I/II dose escalation study of intravenous erbitux (cetuximab) in combination with 5 day weekly oral Xeloda (capecitabine) and preoperative radiotherapy in rectal cancer. - XERXES

niversity College London0 个研究点目标入组 22 人开始时间: 2005年6月2日最近更新: 2019年6月30日

适应症

试验速览

暂无简介。

•Biopsy proven adenocarcinoma of the rectum (tumour <15cm from anal verge); Indication for pre-operative chemoradiotherapy by virtue of partially fixed/unresectable disease and locally advanced disease (T3/T4) where the preoperative MRI confirms the surgeon is unlikely to perform a R0 resection; WHO performance status 0 or 1; Age =18 and fit for surgery.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•Uncontrolled cardiac, respiratory or other disease, or any serious medical or psychiatric disorder that would preclude trial therapy or informed consent; Previous radiotherapy to the pelvis; Previous chemotherapy or radiation for rectal cancer

发起方

niversity College London